BioQTech plc has raised capital as follows: Funding Amount Post-Money Liquidation Round Raised Valuation Preference Series A 15 million 45 million 1.5x Series B 35 million 69 million 2.0x Series C 25 million 80 million 2.0x The table above shows the capital raised and post-money valuations in each funding round and the liquidation preference of investors in each round. Series C investors have the highest seniority followed by Series B then Series A and then common shareholders. None of the funding rounds offered investors participation rights. REQUIRED: D) What will Series A, Series B, Series C, and common shareholders receive if the company is sold for 100 million